Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice.

Oncology reports - 1 Jan 2000

Swiercz R, Keck R W, Skrzypczak-Jankun E, Selman S H, Jankun J

Abstract excerpt

To understand the fundamental determinants of urokinase plasminogen activator (uPA) driven angiogenesis in cancer we studied how inhibition of uPA activity could reduce neovascularization and consequently reduce tumor size in experimental animals. Proteolytic enzymes are required to mediate tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chick Embryo
Share to Endothelium, Vascular
Share to Mice, SCID

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Transplantation

Share to Neovascularization, Pathologic

Share to Plasminogen Activator Inhibitor 1

Share to Serine Proteinase Inhibitors

Share to Umbilical Veins

Source

Identifiers

PMID: 11295064
DOI: 10.3892/or.8.3.463

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-11295064-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice.PMID 11295064Read ↗

Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model.Semantic proximity Read ↗

Plasminogen activator inhibitor-1 and tumour growth, invasion, and metastasisSemantic proximity Read ↗

The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent.Semantic proximity Read ↗

Role of plasminogen activator inhibitor-1 in urokinase's paradoxical in vivo tumor suppressing or promoting effects.Semantic proximity Read ↗

Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.Semantic proximity Read ↗

Investigating the Role of Urokinase in Cancer Metastasis: A ReviewSemantic proximity Read ↗

The role of the plasminogen activation system in angiogenesis and metastasis.Semantic proximity Read ↗

The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding.Semantic proximity Read ↗

Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model.Semantic proximity Read ↗

Plasminogen activator inhibitor type-1 mutants regulate angiogenesis of human umbilical and lung vascular endothelial cells.Semantic proximity Read ↗

SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicingSemantic proximity Read ↗

The urokinase-type plasminogen activator system in cancer metastasis: A reviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.